Vertex Pharmaceuticals 8-K
CEO/CFO change
Jonathan Poole takes over as CFO on Jan. 1, 2027; Charles F. Wagner remains EVP and COO.
Filed 2026-09-01 16:25 ET
- 5.02 Officer/director change
Summary
CFO appointment. Vertex named Jonathan Poole CFO effective 1/1/2027; Charles F. Wagner will leave the CFO role then and remain executive vice president and chief operating officer.
Key Figures
- Poole’s compensation effective 1/1/2027: $0.75M base salary and target annual bonus of 90% of base salary.
- If terminated without cause or he resigns for good reason, Poole is eligible for 100% of his base salary and target annual bonus for the termination year, plus any earned but unpaid bonus from the prior year.
- For qualifying terminations within the change-of-control period, he is eligible for 100% of base salary and target annual bonus, a prorated target bonus, earned unpaid cash incentives, and full vesting of outstanding equity awards. If he elects COBRA, the company will pay medical, dental and life insurance premiums for up to 12 months.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3